Chem Structure (Rivastigmine Transdermal System 1)
Rivastigmine Patch
Product Images NDC 65162-749
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 65162-749). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure A- New (Rivastigmine Transdermal System 10)
This is a description of a Pouch Rivastigmine Patch, which is also known as Rivastigmine Transdermal System. The strength of this medication is 4.6 mg per 24 hours. Protective liners may also be included.*
Figure B (Rivastigmine Transdermal System 11)
This text appears to be a list of body parts where an injury or pain may exist. The list includes the left or right upper arm, left or right side of chest, front I, left or right upper back, and left or right lower back. It may be part of a medical form or questionnaire.*
Figure C- New (Rivastigmine Transdermal System 12)
Figure D (Rivastigmine Transdermal System 13)
Figure E (Rivastigmine Transdermal System 14)
Figure F (Rivastigmine Transdermal System 15)
Figure G (Rivastigmine Transdermal System 16)
Figure H- New (Rivastigmine Transdermal System 17)
4.6 Pouch (Rivastigmine Transdermal System 18)
This is a description for a Rivastigmine Transdermal System for transdermal use. It contains one system prescription for non-varnish area. It is essential to read the enclosed package for proper application of the patch. The recommended usage is once a day, and a new patch should be applied every 24 hours. Applying the patch to the skin area is recommended immediately after it is removed from the pouch. The location of each new patch should be changed. Children should not reach the patch, and adults should keep it for discarding the patch after use. The pouch can be stored between 20°C to 25°C (66°F to 77°F) with excursions allowed between 15°C to 30°C (59°F to 86°F). The manufacturer of the product is Amneal Pharmaceuticals located in Bridgewater, NJ. However, any readable text from the image is missing.*
4.6 Carton (Rivastigmine Transdermal System 19)
This is a set of instructions with more details about a product called Rivastigmine Transdermal System, which is a treatment containing 9 mg of rivastigmine, provided in 5 CR units that release 4.6 mg every 24 hours. The product should be used transdermally, with users applying a new patch after discarding the old one, keeping the product out of reach of children and not using any visibly damaged products. The packaging contains the manufacturer's phone number for more information.*
Figure 1 (Rivastigmine Transdermal System 2)
9.5 mg Pouch (Rivastigmine Transdermal System 20)
This text appears to be a description of a medication called "Rivastigmine Transdermal System" that is administered through a patch for transdermal use. The text includes instructions for application, such as wearing only one patch at a time and replacing it with a new patch every 24 hours. The patch should not be cut and should be applied immediately to intact skin. The text also contains information on storage and warns that the medication should be kept out of reach of children. The medication is distributed by Amneal Pharmaceuticals based in Bridgewater, NJ.*
9.5 Carton (Rivastigmine Transdermal System 21)
The text is a set of instructions and guidelines for the use and disposal of the Rivastigmine Transdermal System, a medication patch used for the treatment of Alzheimer's Disease. It contains information on the dosage, administration, inactive components, and storage of the patch. The instructions also provide guidance on how to safely discard the used patches and keep them out of the reach of children. Contact information for Amneal Pharmaceuticals is also provided for more information.*
13.3 Pouch (Rivastigmine Transdermal System 22)
This is the description of Rivastigle Transdermal System, a type of medication delivered through the skin. It is for transdermal use only and comes in a pouch that contains one system. The medication should not be cut and only one patch must be applied at a time. The patch should be changed every 24 hours, and the location of each new patch must be changed. The medication should be kept out of the reach of children, and the pouch must be retained for discarding the patch after use. The medication should be stored at 20° to 25°C (68° to 77°F). This medication is distributed by Amneal Pharmaceuticals in Bridgewater, NJ.*
13.3 Carton (Rivastigmine Transdermal System 23)
The text provides instructions for discarding the Rivastigmine Transdermal System patch. The patch should be replaced every 24 hours, and the used patch should be disposed of safely out of reach of children. The text also contains information on the inactive components of the patch and on dosage and administration, and provides a website and contact number for further information.*
Carton Inside (Rivastigmine Transdermal System 24)
This text provides instructions on how to use Rivastigmine Transdermal System, a patch medication for treatment. It advises to follow the doctor's instructions and apply only one patch at a time, on clean, dry, hairless, and intact skin at the back, upper arm, or chest. It instructs to cut the pouch, peel one side of the protective liner, apply the sticky side to the skin, peel off the second side, and press the patch firmly to the skin. Lastly, it reminds to wash hands after applying the patch.*
Figure 2 (Rivastigmine Transdermal System 3)
This is a chart showing the concentration of Rivastigmine in ng/mL for three different dosages (4.6, 9.5, and 13.3mg/24 hours) with sample sizes of 22, 22, and 19 respectively, at various time points.*
Figure 3 (Rivastigmine Transdermal System 4)
Figure 4 (Rivastigmine Transdermal System 5)
Figure 5 (Rivastigmine Transdermal System 6)
Figure 6 (Rivastigmine Transdermal System 7)
Figure 7 (Rivastigmine Transdermal System 8)
Figure 8 (Rivastigmine Transdermal System 9)
This appears to be a chart or graph displaying results from a study involving two different treatments using "Rivasigmine patch 4.6 mg/24 hr" and "Rivastigmine patch 9.5 mg/24 hr". However, the text is not entirely clear and may not be useful without additional information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
